Outlook: Zeneca/Astra
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.ANOTHER DAY, another mega-merger, and a cross-border one at that. Zeneca and Astra make a good fit in product and geographical terms. They are also roughly the same size, which means that a genuine merger is at least possible. But the devil is always in the detail. Who will have the upper hand in management terms?
And can the two cultures and nationalities be blended into a harmonious hole? Pharmacia and Upjohn famously degenerated into a snakepit of factional infighting and inter-Continental warring after they merged. From a shareholder value point of view, this is also a far from perfect deal for Zeneca. As the only UK independent of size left, its share price is buoyed by bid hopes. A no premium merger, whatever the cost-cutting benefits and synergies, may seem a poor substitute for an outright takeover.
Certainly Sir Richard Sykes, chairman of Glaxo Welcome, will be watching events with a keen interest. Zeneca was his partner of choice before Welcome, but the price ran away from him and Welcome was more easily attainable.
There is no doubt, however, that he still harbours designs, even though such a takeover would give him almost total hegemony in the UK pharmaceuticals industry. But would he be prepared to pay the price?
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments